All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, January 26, 2023
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

Gold coins and sprouting plants

Billions and billions: Flagship and Arch stand tall in new venture fundings

April 2, 2020
By Lee Landenberger
No Comments
In an uncertain time that’s dominated by COVID-19, Flagship Pioneering Inc. and Arch Venture Partners collectively raised a massive $2.56 billion to fund new company creation and growth.
Read More
Scientific data illustration
It’s not FAIR!

Accelerated by COVID-19, science changes will outlast pandemic

April 2, 2020
By Anette Breindl
No Comments
COVID-19 has disrupted science in the way it has disrupted everything else. In the short term, universities have largely closed shop as a way to maximize social distancing, and lots of science – or at least, lots of bench work – is not getting done.
Read More
Gold chain link engraved with "partnership"

I-Mab scores regional deal for two candidates; submits IND for COVID-19 candidate in U.S. and South Korea

April 2, 2020
By David Ho
No Comments
HONG KONG – China’s I-Mab Biopharma Co. Ltd. has entered a strategic partnership with Indonesia’s PT Kalbe Genexine Biologics (KG Bio). Through the deal, KG Bio will receive the right of first negotiation to commercialize two I-Mab-discovered candidates in the ASEAN and MENA regions as well as Sri Lanka.
Read More
Lung cancer illustration

Another COVID-19 casualty: Ose shutters phase III Tedopi trial in NSCLC despite positive interim analysis

April 2, 2020
By Cormac Sheridan
No Comments
DUBLIN – Ose Immunotherapeutics SA finds itself in the difficult place of hitting the primary endpoint of the first part of a phase III trial of Tedopi, a therapeutic vaccine, in non-small-cell lung cancer (NSCLC) while having to terminate the study without completing the crucial second part.
Read More

Regulatory actions for March 31, 2020

April 2, 2020
No Comments
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Cytosorbents, Enlightenvue, Qiagen, Siemens Healthineers.
Read More

Regulatory actions for April 2, 2020

April 2, 2020
No Comments
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Affimed, Applied, Celularity, Fera, Nicox, Pfizer, Pharmamar, Seattle Genetics.
Read More

Other news to note for April 2, 2020

April 2, 2020
No Comments
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: AC Immune, Adaptive, Advanz, Aicuris, Alnylam, Amgen, Ansun, Apeptico, Astrazeneca, Aurobindo, Axxam, Bharat, Bioaegis, Celator, Celularity, Cobra, Combigene, Cortexyme, Cytodyn, Elevation, Ennaid, ERS, Evotec, Flugen, Foamix, 14ner, Ipsen, Kite, La Jolla, Leo, Menlo, Merck, Merrimack, Novartis, Noxopharm, Paratek, Perrigo, Persephone, Ra, Redhill, Relief, Sandoz, Serimmune, Sonnet, Sorrento, Tetra, Teva, UCB, Vir, Zealand.
Read More

In the clinic for April 2, 2020

April 2, 2020
No Comments
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Algernon, Apeiron, Arena, Atara, Athera, Axial, Biogen, Dermavant, Eiger, Fulcrum, Geron, I-Mab, Mateon, Merck, Moleculin, Momenta, Noxxon, Oncolytics, Rhovac, Valbiotis, VBL, Xbrane, Zymeworks.
Read More

Other news to note for March 30, 2020

April 2, 2020
No Comments
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: 3D Medicines, Alphamab, Altimmune, Amgen, Aptorum, Aravive, Astrazeneca, Bellerophon, Benitec, Cobra, Compass, Covar, Curetis, Diverse, Forty Seven, Genexine, Gigagen, Gilead, Harmony, Hoth, I-Mab, Imaginab, IMV, Isoprene, Lifemax, Moderna, Nanotx, Noveome, Numab, Olix, Ono, Opgen, Plus, Simcere, Surrozen.
Read More
Radlogics-corona-score.png

CT scans interpreted by AI can help diagnose coronavirus

April 1, 2020
By Annette Boyle
No Comments
An artificial intelligence-based system can accurately detect COVID-19 using thoracic CT scans in patients with respiratory symptoms, according to a preprint study published on arXiv.org. The system can also help monitor patients with the disease. Other teams have employed AI to speed diagnosis and develop clarity on the signature appearance of the disease in the lungs of symptomatic patients.
Read More
Previous 1 2 … 440 441 442 443 444 445 446 447 448 … 495 496 Next

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan. 26, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 26, 2022.
  • Biogen, Eisai win FDA clearance for AD therapy Leqembi

    BioWorld
    As expected, the U.S. FDA gave its go-ahead to lecanemab, an amyloid-beta binder for mild cognitive impairment caused by Alzheimer’s disease (AD) and mild AD –...
  • Stem-cells2.png

    J.P. Morgan Healthcare Conference: ‘Bright’ year ahead for cell, gene therapies, says ARM

    BioWorld
    After long years of painstaking work, the commercialization of cell and gene therapies picked up pace in 2022, with multiple approvals. More progress is expected...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing